Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 9/20 | 0.63 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 3/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6185183 | 1.00 | APP (0.63) | APPKCNA3LTA4HTAAR1ALDH1A1 | |
| SCHEMBL11867619 | 0.90 | APP (0.61) | APPRXRARXRB | |
| SCHEMBL497461 | 0.84 | KCNA3 (0.63) | APPKCNA3LTA4HTAAR1ALDH1A1 | |
| SCHEMBL2893827 | 0.84 | KCNA3 (0.65) | APPKCNA3LTA4HTAAR1ALDH1A1 | |
| SCHEMBL4530838 | 0.84 | KCNA3 (0.73) | APPKCNA3LTA4HTAAR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL10555789 | 0.82 | KCNA3 (0.60) | APPKCNA3LTA4HTAAR1ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL28919640 | 0.82 | KCNA3 (0.60) | APPKCNA3LTA4HTAAR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL10519295 | 0.82 | KCNA3 (0.60) | APPKCNA3LTA4HTAAR1ALDH1A1 | |
| SCHEMBL13696303 | 0.80 | LTA4H (0.67) | KCNA3LTA4HPLA2G2A | |
| SCHEMBL15383159 | 0.78 | LSS (0.52) | KCNA3LTA4HALDH1A1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119201-B2 | Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1501515-B1 | TRIARYL-OXY-ARYLOXY-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | PFIZER PROD INC (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-1501515-A1 | TRIARYL-OXY-ARYLOXY-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | Pfizer Products Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040006057-A1 | Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER PRODUCTS INC. | 2004-01-08 | — | — | US | disclosed |
| WO-2003090752-A1 | TRIARYL-OXY-ARYLOXY-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006057-A1 | Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors | MMP8, MMP9, MMP1 | APP 2950/4885KCNA3 4766/4885LTA4H 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.